2265 Upper Middle Road East
Suite 602
Oakville, ON L6H 0G5
Canada
289-910-0850
https://www.cardiolrx.com
Settore/i: Healthcare
Settore: Drug Manufacturers - Specialty & Generic
Impiegati a tempo pieno:
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. David G. Elsley MBA | President, CEO & Director | 548,39k | N/D | N/D |
Mr. Christopher J. Waddick C.A., C.M.A., CPA, CMA, MBA | CFO, Corporate Secretary & Director | 216,1k | N/D | N/D |
Mr. Bernard Lim B.Sc. | Chief Operating Officer | 378,18k | N/D | N/D |
Dr. Andrew Warwick Hamer M.D. | Chief Medical Officer & Head of Research & Development | 547,27k | N/D | 1962 |
Trevor Burns | Investor Relations | N/D | N/D | N/D |
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.
L'ISS Governance QualityScore di Cardiol Therapeutics Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.